Physician profile
Christopher S Boylan
NPI 1285629501
$5,664.99
in general payments reported to CMS, 2019-2025
32 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $320 · 2021: $926 · 2022: $1,264 · 2023: $745 · 2024: $279 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $969.52 | 2019-2023 | Xarelto |
| Amgen INC. | $492.63 | 2019-2025 | Repatha |
| Inari Medical, INC. | $451.69 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $361.52 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $354.35 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $352.46 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $267.00 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $257.65 | 2019-2023 | Eliquis |
| Heartflow, INC. | $242.68 | 2021-2024 | |
| Medtronic, INC. | $196.82 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Linq II |
| Boston Scientific Corporation | $182.56 | 2020-2025 | Versacross Access Solution, Eluvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.04 | 2019-2023 | Jardiance |
| Abbott Laboratories | $148.07 | 2019-2025 | Diamondback Peripheral, Perclose Prostyle, Diamondback Coronary |
| Pfizer INC. | $139.43 | 2019-2023 | |
| Abiomed | $133.06 | 2021-2023 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $109.43 | 2019-2021 | |
| Medtronic Vascular, INC. | $101.57 | 2019-2020 | |
| Cook Medical LLC | $95.09 | 2021-2025 | Zilver Ptx, Cook Celect |
| Irhythm Technologies, INC. | $87.59 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $85.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.90 | 2021-2023 | |
| Cardiva Medical, INC. | $73.03 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Cardiovascular Systems INC. | $59.96 | 2022-2023 | Diamondback Coronary |
| Amarin Pharma, INC. | $58.48 | 2019 | |
| W. L. Gore & Associates, INC. | $47.72 | 2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Biotronik INC. | $45.91 | 2019 | |
| Angiodynamics, INC. | $35.17 | 2021-2023 | Auryon Laser System 100-120 Vac |
| Teleflex LLC | $26.22 | 2021 | |
| Gilead Sciences, INC. | $16.89 | 2019 | |
| Altathera Pharmaceuticals LLC | $15.83 | 2022 | |
| Medicomp INC | $12.07 | 2019 | |
| Getinge USA Sales, LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.